128 related articles for article (PubMed ID: 27570805)
1. Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Norek K; Patel RG; McLure KG; Young PR; Gordon A; Kulikowski E; Johansson J; Sweeney M; Wong NC
Data Brief; 2016 Sep; 8():1280-8. PubMed ID: 27570805
[TBL] [Abstract][Full Text] [Related]
2. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
3. Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.
Dhulkifle H; Diab MI; Algonaiah M; Korashy HM; Maayah ZH
ACS Pharmacol Transl Sci; 2024 Mar; 7(3):546-559. PubMed ID: 38481679
[TBL] [Abstract][Full Text] [Related]
4. The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation
Wasiak S; Fu L; Daze E; Gilham D; Rakai BD; Stotz SC; Tsujikawa LM; Sarsons CD; Studer D; Rinker KD; Jahagirdar R; Wong NCW; Sweeney M; Johansson JO; Kulikowski E
Transl Neurosci; 2023 Jan; 14(1):20220332. PubMed ID: 38222824
[TBL] [Abstract][Full Text] [Related]
5. Benefit of Apabetalone on Plasma Proteins in Renal Disease.
Wasiak S; Tsujikawa LM; Halliday C; Stotz SC; Gilham D; Jahagirdar R; Kalantar-Zadeh K; Robson R; Sweeney M; Johansson JO; Wong NC; Kulikowski E
Kidney Int Rep; 2018 May; 3(3):711-721. PubMed ID: 29854980
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Calosing C; Jahagirdar R; Johansson J; Sweeney M; Wong NC; Kulikowski E
J Cardiovasc Transl Res; 2017 Aug; 10(4):337-347. PubMed ID: 28567671
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
9. BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire.
Najafova Z; Tirado-Magallanes R; Subramaniam M; Hossan T; Schmidt G; Nagarajan S; Baumgart SJ; Mishra VK; Bedi U; Hesse E; Knapp S; Hawse JR; Johnsen SA
Nucleic Acids Res; 2017 Jan; 45(1):127-141. PubMed ID: 27651452
[TBL] [Abstract][Full Text] [Related]
10. BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.
Andrieu G; Tran AH; Strissel KJ; Denis GV
Cancer Res; 2016 Nov; 76(22):6555-6567. PubMed ID: 27651315
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
12. BRD4 regulates fructose-inducible lipid accumulation-related genes in the mouse liver.
Yamada A; Honma K; Mochizuki K; Goda T
Metabolism; 2016 Oct; 65(10):1478-88. PubMed ID: 27621183
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
14. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
15. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation.
Nguyen TH; Maltby S; Eyers F; Foster PS; Yang M
PLoS One; 2016; 11(9):e0163392. PubMed ID: 27657907
[TBL] [Abstract][Full Text] [Related]
17. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
[TBL] [Abstract][Full Text] [Related]
18. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
19. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Nicholls SJ; Schwartz GG; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Ray KK;
Cardiovasc Diabetol; 2021 Jan; 20(1):13. PubMed ID: 33413345
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response
Wasiak S; Gilham D; Daze E; Tsujikawa LM; Halliday C; Stotz SC; Rakai BD; Fu L; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Cardiovasc Ther; 2020; 2020():9397109. PubMed ID: 32821285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
